Cure My Disease

Don't miss your cure!

 Log in / Sign up

Gene therapy injection aims to lower eye pressure in glaucoma

NCT ID NCT06921317

Recruiting now Disease control Sponsor: IVIEW Therapeutics Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early study tests a new gene therapy called GVB-2001 for people with primary open-angle glaucoma. The treatment is given as an injection into the eye to help lower high pressure inside the eye. About 6 adults aged 18 to 75 with glaucoma for at least a year will take part. The main goals are to check if the treatment is safe and if it can reduce eye pressure.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY OPEN ANGLE GLAUCOMA (POAG) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

congenital stationary night blindness autosomal dominant 1 glaucoma open-angle glaucoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PRIMARY OPEN ANGLE GLAUCOMA (POAG)

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • The First Affiliated Hospital of Soochow University

    RECRUITING

    Suzhou, Jiangsu, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Email: •••••@•••••